Fig. 2.

Non–small cell lung cancer mutations.

Although more than one-third of driver mutations in non–small cell lung cancer (NSCLC) are still unknown, approximately one-half of primary single mutations have been identified. The approval of targeted therapies for epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinomas has led to a better understanding of individual driver and resistance mutations upon tumor progression.^{17 , 18} (Large pie chart adapted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.^{17 , 18})